NOTES OF A MEETING OF THE Z8 STEERING GROUP

PRESENT:	Dr R V McIntosh	Mr J Sinclair
	Dr P R Foster	Mr T A McQuillan
	Mr R Lines	Mr R Howieson
	Mr N Docherty	Dr B Cuthbertson
	Mr R Oliver	
DATED:	18 December 1986	

The following points were agreed:

1. Plasma conditioning is still seen as a problem which requires attention. G Neillie is currently putting together a summary of current temperature data and a meeting of interested parties will be called early in the New Year.

2. Z8 6-024 was the first to employ cold extraction, with buffers and centrifuge being held at +10 °C. This gave a reduced fibrinogen content but FVIII activity was lost between Tris extraction and Post-formulation. It is believed that this may have occurred due to cold filtration through the U 220 filter. It was agreed that this filtration step was of limited value and could be dropped.

3. Z8 024-5 was frozen post-formulation and thawed. This rework step was very satisfactory with a 96% recovery. It is clear that future lots could be held frozen post-formulation, if necessary.

4. Two-stage freezing of three batches examined so far all gave amporphous product but on heating some colour variability is still noted.

   A significant loss of potency was noted over the drying stages of 6-022 and 6-023.

   An SMJR freezing experiment indicated that a less dense crystal structure and more rapid freezing occurs if the supercooling stage is carried out at -5 °C. At a further meeting, J Sinclair, R McIntosh and B Cuthbertson agreed that the small batch Z8 6-027 would be supercooled at this temperature.

5. To date, cycle G has been higly reproducible. Two or three more manual runs will be carried out and an automatic tape will then be cut.

6. All batches manufactured in 1986 will be heated at 75 °C/72 hours with 20 vials from each batch being heated at 80 °/72 hours.

7. Z8 6-005 gave good results when thawed and freeze-dried after two-stage freezing. Batch Z8 6-006 will be treated similarly once the two-stage freezing conditions have been optimised.

8. No clinical feedback has yet been received. If none is forthcoming in the near future then we may have to revert to the manufacture of NY.

9. J Sinclair wondered if donor exposure was still a limiting factor on batch size. This will need further discussion.

B Cuthbertson
22/12/86